Danish article from the patient journal “Magasinet om Rygsøjlegigt”, May 2024. Plain language summary of the scientific publication from EuroSpA: “Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe” by Michelsen et. al. (publication A2.1)
You can read the original article published in The Lancet Regional Health – Europe in 2023 here: https://www.sciencedirect.com/science/article/pii/S2666776223001254
Danish:
“Switching between TNFi drugs for patients with axial spondyloarthritis”
Plain language summary of the scientific publication from EuroSpA: “Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching” by Linde et. al. (publication 1.4)
You can read the original article published in Rheumatology in 2023 here: https://doi.org/10.1093/rheumatology/kead494
English:
Danish:
“Age, disease duration, sex and other common factors may predict which patients with psoriatic arthritis achieve inactive disease when treated with TNF inhibitors”
Plain language summary of the scientific publication from EuroSpA: “Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries” by Linde, Ørnbjerg, Georgiadis et. al. (publication 4.1)
You can read the original article published in Seminars in Arthritis and Rheumatism in 2022 here: https://doi.org/10.1093/rheumatology/kead284
English:
Danish:
“Age, sex, smoking status and other common factors may predict which patients with axial spondyloarthritis achieve inactive disease when treated with TNF inhibitors”
Plain language summary of the scientific publication from EuroSpA: “Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors – Data from the EuroSpA collaboration” by Ørnbjerg, Linde, Georgiadis et. al. (publication 4.2)
You can read the original article published in Seminars in Arthritis and Rheumatism in 2022 here: https://www.sciencedirect.com/science/article/pii/S0049017222001329?via%3Dihub
English:
“One-third of patients with axial spondyloarthritis experience a period without pain when treated with TNFi”
Plain language summary of the scientific publication from EuroSpA: “One-Third of European Patients with Axial Spondyloarthritis
Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment” by Ørnbjerg, Rugbjerg et. al. (publication 2.2)
You can read the original article published in The Journal of Rheumatology in 2023 here: https://www.jrheum.org/content/early/2023/01/10/jrheum.220459.long
English:
Danish: